14. (New) The composition of claim 1 wherein the substances having a biological regulatory effect or physiological activity for mammals are selected from the group consisting of docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), DHA- and/or EPA-containing fish oil, linolic acid, γ -linolenic acid, α -linolenic acid, evening primrose oil, borage oil, lecithin, octacosanol, rosemary, sage, γ -oryzanol, β -carotene, palm carotene, perilla oil, chitin, chitosan, royal jelly and propolis, oil-soluble vitamins, derivatives of oil-soluble vitamins, water-soluble vitamins and derivatives of water-soluble vitamins.

15. (New) The composition of claim 14 wherein the derivatives of oil-soluble vitamins are selected from the group consisting of vitamin A, vitamin D, vitamin E, vitamin F and vitamin K; and the derivatives of water-soluble vitamins are selected from the group consisting of vitamin B₁, vitamin B₂, vitamin B₆, vitamin B₁, vitamin C, vitamin L, vitamin P, nicotinic acid, pantothenic acid and choline.

REMARKS

Further and favorable reconsideration is respectfully requested in view of the foregoing amendments and following remarks.

Initially, with regard to the restriction requirement, Applicants note that claim 13 was grouped with the elected claims, and that, as indicated in the response filed May 7, 2001, Applicants should be given an opportunity to rejoin claim 11 (and claim 13) upon allowance of the elected claims. That is, if the subject matter of claim 1 is patentable, as will be supported by the following remarks, then claims 11 and 13 are also patentable because they depend on claim 1. In such case, Applicants should be given an opportunity to rejoin claims 11 and 13.

In response to the rejection of claims 1-10 and 12 under the second paragraph of 35 U.S.C. § 112, claim 1 has been amended to refer to substances having a biological regulatory effect or